LU91446I2 - "Efavirenz/emtricitabine/fumarate de ténolovir disoproxil" - Google Patents

"Efavirenz/emtricitabine/fumarate de ténolovir disoproxil"

Info

Publication number
LU91446I2
LU91446I2 LU91446C LU91446C LU91446I2 LU 91446 I2 LU91446 I2 LU 91446I2 LU 91446 C LU91446 C LU 91446C LU 91446 C LU91446 C LU 91446C LU 91446 I2 LU91446 I2 LU 91446I2
Authority
LU
Luxembourg
Prior art keywords
tenolovir
emtricitabine
efavirenz
hiv
disoproxil fumarate
Prior art date
Application number
LU91446C
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26733517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LU91446I2 publication Critical patent/LU91446I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU91446C 1992-08-07 2008-05-27 "Efavirenz/emtricitabine/fumarate de ténolovir disoproxil" LU91446I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92660792A 1992-08-07 1992-08-07
US5480593A 1993-04-27 1993-04-27

Publications (1)

Publication Number Publication Date
LU91446I2 true LU91446I2 (fr) 2008-07-28

Family

ID=26733517

Family Applications (2)

Application Number Title Priority Date Filing Date
LU90709C LU90709I2 (fr) 1992-08-07 2000-12-20 Efavirenz optionnellement sous forme d'un sel pharmaceutiquement acceptable
LU91446C LU91446I2 (fr) 1992-08-07 2008-05-27 "Efavirenz/emtricitabine/fumarate de ténolovir disoproxil"

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU90709C LU90709I2 (fr) 1992-08-07 2000-12-20 Efavirenz optionnellement sous forme d'un sel pharmaceutiquement acceptable

Country Status (37)

Country Link
EP (1) EP0582455B1 (fr)
JP (1) JPH0780860B2 (fr)
KR (1) KR100272387B1 (fr)
CN (3) CN1051767C (fr)
AT (1) ATE197295T1 (fr)
AU (1) AU670300B2 (fr)
BG (1) BG62612B1 (fr)
CA (1) CA2101572C (fr)
CZ (1) CZ290447B6 (fr)
DE (4) DE69329608T2 (fr)
DK (1) DK0582455T3 (fr)
DZ (1) DZ1707A1 (fr)
ES (1) ES2151897T3 (fr)
FI (1) FI115457B (fr)
GR (1) GR3034754T3 (fr)
HK (1) HK1009267A1 (fr)
HR (1) HRP931102B1 (fr)
HU (1) HU223076B1 (fr)
IL (1) IL106507A (fr)
LU (2) LU90709I2 (fr)
LV (1) LV12719B (fr)
MX (1) MX192812B (fr)
MY (1) MY109834A (fr)
NL (2) NL300032I2 (fr)
NO (3) NO304886B1 (fr)
NZ (1) NZ255216A (fr)
PL (2) PL175615B1 (fr)
PT (1) PT582455E (fr)
RO (1) RO113641B1 (fr)
RU (1) RU2186775C2 (fr)
SG (1) SG52698A1 (fr)
SI (1) SI9300419B (fr)
SK (1) SK282276B6 (fr)
TW (2) TW382014B (fr)
UA (1) UA42699C2 (fr)
WO (1) WO1994003440A1 (fr)
YU (1) YU49439B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
AU3736197A (en) * 1996-07-26 1998-02-20 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
CA2279198C (fr) * 1997-02-05 2009-04-14 Merck & Co., Inc. Procede de cristallisation d'un inhibiteur de transcriptase inverse utilisant un antisolvant
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
BR9808486A (pt) * 1997-04-07 2000-05-23 Du Pont Pharm Co Processo para a preparação de um composto
US6124302A (en) * 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
KR20010023584A (ko) * 1997-09-03 2001-03-26 폴락 돈나 엘. 2ｒ-[1-하이드록시-1-트리플루오로메틸-3-사이클로프로필프로핀-2일]-4-클로로아닐린의 광학 순도를 향상시키는 방법
US5952528A (en) * 1997-09-03 1999-09-14 Merck & Co., Inc. Process for enhancing the optical purity
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
EP1091939A1 (fr) * 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company Quinoline-2(1h)-ones substituees utiles comme inhibiteurs de la transcriptase inverse du vih
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
US6946469B2 (en) 2001-03-28 2005-09-20 Bristol-Myers Squibb Pharma Company Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
RU2344128C2 (ru) 2003-03-24 2009-01-20 Ф.Хоффманн-Ля Рош Аг Бензилпиридазиноны как ингибиторы обратной транскриптазы
WO2009044788A1 (fr) * 2007-10-05 2009-04-09 Banyu Pharmaceutical Co., Ltd. Dérivé de benzoxazinone
GB0720503D0 (en) 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
EP2448917A2 (fr) 2009-07-03 2012-05-09 Archimica GmbH Procédé d addition énantiosélective de nucléophiles carbonés organométalliques sur des trifluorométhylcétones et utilisation du procédé dans la synthèse d inhibiteurs de la transcriptase inverse du vih
AU2011209788C1 (en) 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy
EP2471783A1 (fr) 2010-12-23 2012-07-04 Esteve Química, S.A. Nouvelle forme polymorphe de l'éfavirenz
CN103664816B (zh) * 2011-01-06 2016-03-02 中国科学院上海有机化学研究所 Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN102675125B (zh) * 2011-03-15 2015-02-18 中国科学院上海有机化学研究所 一种4-氯-2-三氟乙酰基苯胺及其类似物的简便高效合成方法
WO2020164218A1 (fr) 2019-02-15 2020-08-20 Fujian Yongjing Technology Co., Ltd Nouveau procédé de réaction de friedel-crafts et catalyseur associé
CN110372625B (zh) * 2019-08-06 2022-11-01 常州大学 蓝光照射制备4-烷甲基-4-芳基-1,3-苯并噁嗪-2(4h)-酮的方法
CN113106473B (zh) * 2021-04-14 2022-02-18 南京工业大学 一种通过连续电化学微反应器装置制备1,3-苯并噁嗪衍生物的方法
EP4416134A1 (fr) * 2021-10-15 2024-08-21 Merck Sharp & Dohme LLC Dérivés de benzoxazinone utilisés comme agents cytotoxiques sélectifs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3562621A (en) * 1967-07-26 1971-02-09 Technipower Inc Inrush current limiting circuit for rectifier circuits with capacitive load
DE3217012A1 (de) * 1982-05-06 1983-11-10 Dr. Karl Thomae Gmbh, 7950 Biberach Benzoxazin-2-one, deren herstellung und diese verbindungen enthaltende arzneimittel
CA2032259A1 (fr) * 1989-12-18 1991-06-19 Wayne J. Thompson Inhibiteurs de la protease du vih utiles dans le traitement du sida
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors

Also Published As

Publication number Publication date
RO113641B1 (ro) 1998-09-30
ES2151897T3 (es) 2001-01-16
HU223076B1 (hu) 2004-03-01
LV12719A (lv) 2001-09-20
JPH0780860B2 (ja) 1995-08-30
SK16195A3 (en) 1995-07-11
NO304886B1 (no) 1999-03-01
BG99383A (bg) 1995-09-29
SI9300419A (en) 1994-06-30
DK0582455T3 (da) 2000-11-27
HRP931102B1 (en) 2001-06-30
CN1051767C (zh) 2000-04-26
GR3034754T3 (en) 2001-02-28
LV12719B (lv) 2001-12-20
NL300032I2 (nl) 2001-04-02
JPH06184124A (ja) 1994-07-05
NL300032I1 (fr) 2001-02-01
PL176679B1 (pl) 1999-07-30
EP0582455A1 (fr) 1994-02-09
TW382014B (en) 2000-02-11
DE10199013I1 (de) 2001-05-23
ATE197295T1 (de) 2000-11-15
CZ290447B6 (cs) 2002-07-17
BG62612B1 (bg) 2000-03-31
SK282276B6 (sk) 2002-01-07
HRP931102A2 (en) 1997-10-31
PL307348A1 (en) 1995-05-15
NO950424L (no) 1995-04-06
AU670300B2 (en) 1996-07-11
HUT71219A (en) 1995-11-28
LU90709I2 (fr) 2002-02-04
DE69329608D1 (de) 2000-12-07
CN1250652A (zh) 2000-04-19
NZ255216A (en) 1996-05-28
MX9304775A (es) 1994-05-31
PL175615B1 (pl) 1999-01-29
KR100272387B1 (ko) 2000-11-15
MY109834A (en) 1997-08-30
MX192812B (es) 1999-07-30
SG52698A1 (en) 1998-09-28
FI950508A0 (fi) 1995-02-06
CN1090277A (zh) 1994-08-03
IL106507A0 (en) 1993-11-15
CN1107505C (zh) 2003-05-07
CA2101572A1 (fr) 1994-02-08
TWI233436B (en) 2005-06-01
NO2000004I1 (no) 2000-06-16
EP0582455B1 (fr) 2000-11-02
DE69329608T2 (de) 2001-05-03
FI950508A (fi) 1995-02-06
CZ28695A3 (en) 1995-09-13
YU49439B (sh) 2006-03-03
WO1994003440A1 (fr) 1994-02-17
FI115457B (fi) 2005-05-13
HK1009267A1 (en) 1999-05-28
DE122008000034I1 (de) 2008-10-02
PT582455E (pt) 2001-03-30
DZ1707A1 (fr) 2002-02-17
NO2008008I1 (no) 2008-06-30
IL106507A (en) 1997-11-20
CA2101572C (fr) 2001-08-28
SI9300419B (sl) 2002-10-31
CN1221608A (zh) 1999-07-07
RU2186775C2 (ru) 2002-08-10
CN1318031C (zh) 2007-05-30
YU53093A (sh) 1996-10-09
NL300347I1 (nl) 2008-07-01
HU9500366D0 (en) 1995-03-28
AU4449693A (en) 1994-02-10
UA42699C2 (uk) 2001-11-15
KR950702970A (ko) 1995-08-23
RU95107403A (ru) 1996-11-20
NO950424D0 (no) 1995-02-06
DE10199013I2 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
LU91446I2 (fr) "Efavirenz/emtricitabine/fumarate de ténolovir disoproxil"
ATE175412T1 (de) Hiv-protease-inhibitoren
ATE230610T1 (de) Hiv protease hemmer in pharmazeutischen zusammensetzungen zur behandlung von aids
ATE215952T1 (de) Hiv-proteaseinhibitoren
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.